UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors

International journal of molecular sciences, 2018-08, Vol.19 (8), p.2367

2018

Volltextzugriff (PDF)

Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib

Chemical research in toxicology, 2018-07, Vol.31 (7), p.570-584

2018

Volltextzugriff (PDF)

Detoxication versus Bioactivation Pathways of Lapatinib In Vitro: UGT1A1 Catalyzes the Hepatic Glucuronidation of Debenzylated Lapatinib

Drug metabolism and disposition, 2021-03, Vol.49 (3), p.233-244

2021

Volltextzugriff (PDF)

CBD and THC in Special Populations: Pharmacokinetics and Drug-Drug Interactions

Pharmaceutics, 2024-04, Vol.16 (4), p.484

2024

Volltextzugriff (PDF)

A Review of CYP-Mediated Drug Interactions: Mechanisms and In Vitro Drug-Drug Interaction Assessment

Biomolecules (Basel, Switzerland), 2024-01, Vol.14 (1), p.99

2024

Volltextzugriff (PDF)

Formation of CYP3A‐specific metabolites of ibrutinib in vitro is correlated with hepatic CYP3A activity and 4β‐hydroxycholesterol/cholesterol ratio

Clinical and translational science, 2023-02, Vol.16 (2), p.279-291

2023

Volltextzugriff (PDF)

Cytochrome P450-Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol

Drug metabolism and disposition, 2021-10, Vol.49 (10), p.882-891

2021

Volltextzugriff (PDF)

Verifying in vitro‐determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically‐based pharmacokinetic modeling

CPT: pharmacometrics and systems pharmacology, 2023-03, Vol.12 (3), p.320-332

2023

Volltextzugriff (PDF)

Impact of Interindividual Variability in CYP3A Activity on Ibrutinib and Venetoclax Metabolism In Vitro

The FASEB journal, 2022-05, Vol.36 (S1), p.n/a

2022

Volltextzugriff (PDF)

Advances and Challenges in Modeling Cannabidiol Pharmacokinetics and Hepatotoxicity

Drug metabolism and disposition, 2024-05, Vol.52 (6), p.508-515

2024

Volltextzugriff (PDF)

Kinase Inhibitors FDA Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities

Drug metabolism and disposition, 2024-05, Vol.52 (6), p.479-492

2024

Volltextzugriff (PDF)

Novel approaches to characterize individual drug metabolism and advance precision medicine

Drug metabolism and disposition, 2023-10, Vol.51 (10), p.1238-1253

2023

Volltextzugriff (PDF)

Formation of the Major Circulating Metabolite of Cannabidiol by Non‐P450, Cytosolic Enzymes

The FASEB journal, 2022-05, Vol.36 (S1), p.n/a

2022

Volltextzugriff (PDF)

Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors

Circulation research, 2021-06, Vol.128 (12), p.1973-1987

2021

Volltextzugriff (PDF)

Cytosolic Enzymes Generate Cannabinoid Metabolites 7‑Carboxycannabidiol and 11-Nor-9-carboxytetrahydrocannabinol

ACS medicinal chemistry letters, 2023-05, Vol.14 (5), p.614-620

2023

Volltextzugriff (PDF)

Induction of Cytochrome P450 (CYP) 1A2 and CYP3A Influences Sunitinib Metabolism and Bioactivation in Primary Human Hepatocytes

The FASEB journal, 2022-05, Vol.36 (S1), p.n/a

2022

Volltextzugriff (PDF)

Cytochromes P450 2C8 and 3A Catalyze the Metabolic Activation of the Tyrosine Kinase Inhibitor Masitinib

Chemical research in toxicology, 2022-09, Vol.35 (9), p.1467-1481

2022

Volltextzugriff (PDF)

Case Study 11: Considerations for Enzyme Mapping Experiments-Interaction Between the Aldehyde Oxidase Inhibitor Hydralazine and Glutathione

Methods in molecular biology (Clifton, N.J.), 2021, Vol.2342, p.809

2021

Volltextzugriff (PDF)

Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation

Drug metabolism and disposition, 2019-11, Vol.47 (11), p.1257-1269

2019

Volltextzugriff (PDF)

Interindividual Variability in Cytochrome P450 3A and 1A Activity Influences Sunitinib Metabolism and Bioactivation

Chemical research in toxicology, 2022-05, Vol.35 (5), p.792-806

2022

Volltextzugriff (PDF)

Impact of cytochrome P450 variation on meperidine N-demethylation to the neurotoxic metabolite normeperidine

Xenobiotica, 2020-02, Vol.50 (2), p.132-145

2020

Volltextzugriff (PDF)

Vaping additives cannabinoid oil and vitamin E acetate adhere to and damage the human airway epithelium

Journal of applied toxicology, 2023-05, Vol.43 (5), p.680-693

2023

Volltextzugriff (PDF)

Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib

Drug metabolism and disposition, 2016-10, Vol.44 (10), p.1584-1597

2016

Volltextzugriff (PDF)

HU-331 and Oxidized Cannabidiol Act as Inhibitors of Human Topoisomerase IIα and β

Chemical research in toxicology, 2018-02, Vol.31 (2), p.137-144

2018

Volltextzugriff (PDF)

Biotransformation novel advances - 2021 year in review

Drug metabolism reviews, 2022-08, Vol.54 (3), p.207-245

2022

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(44)

Sprache

Englisch
(44)

Erscheinungsjahr

n.n

Thema

Science & Technology
(27)
Life Sciences & Biomedicine
(24)
Humans
(23)
Pharmacology & Pharmacy
(19)
Biotransformation
(7)
Chemistry
(6)
Chemistry, Multidisciplinary
(6)
Metabolism
(6)
Physical Sciences
(6)
Activation, Metabolic
(5)
Animals
(5)
Cytochrome P-450 Cyp3a - Metabolism
(5)
Cytochrome P-450 Enzyme System - Metabolism
(5)
Cytochrome P450
(5)
Drug Metabolism
(5)
Microsomes, Liver - Metabolism
(5)
Toxicology
(5)
Cannabidiol
(4)
Chemistry, Medicinal
(4)
Drug Interactions
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors

Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib

Detoxication versus Bioactivation Pathways of Lapatinib In Vitro: UGT1A1 Catalyzes the Hepatic Glucuronidation of Debenzylated Lapatinib

CBD and THC in Special Populations: Pharmacokinetics and Drug-Drug Interactions

A Review of CYP-Mediated Drug Interactions: Mechanisms and In Vitro Drug-Drug Interaction Assessment

Formation of CYP3A‐specific metabolites of ibrutinib in vitro is correlated with hepatic CYP3A activity and 4β‐hydroxycholesterol/cholesterol ratio

Cytochrome P450-Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol

Verifying in vitro‐determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically‐based pharmacokinetic modeling

Impact of Interindividual Variability in CYP3A Activity on Ibrutinib and Venetoclax Metabolism In Vitro

Advances and Challenges in Modeling Cannabidiol Pharmacokinetics and Hepatotoxicity

Kinase Inhibitors FDA Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities

Novel approaches to characterize individual drug metabolism and advance precision medicine

Formation of the Major Circulating Metabolite of Cannabidiol by Non‐P450, Cytosolic Enzymes

Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors

Cytosolic Enzymes Generate Cannabinoid Metabolites 7‑Carboxycannabidiol and 11-Nor-9-carboxytetrahydrocannabinol

Induction of Cytochrome P450 (CYP) 1A2 and CYP3A Influences Sunitinib Metabolism and Bioactivation in Primary Human Hepatocytes

Cytochromes P450 2C8 and 3A Catalyze the Metabolic Activation of the Tyrosine Kinase Inhibitor Masitinib

Case Study 11: Considerations for Enzyme Mapping Experiments-Interaction Between the Aldehyde Oxidase Inhibitor Hydralazine and Glutathione

Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation

Interindividual Variability in Cytochrome P450 3A and 1A Activity Influences Sunitinib Metabolism and Bioactivation

Impact of cytochrome P450 variation on meperidine N-demethylation to the neurotoxic metabolite normeperidine

Vaping additives cannabinoid oil and vitamin E acetate adhere to and damage the human airway epithelium

Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib

HU-331 and Oxidized Cannabidiol Act as Inhibitors of Human Topoisomerase IIα and β

Biotransformation novel advances - 2021 year in review

Suchergebnisse filtern